[HT-01] Large scale multicenter studies of dementia

[HT-01-4] THE DOMINANTLY INHERITED ALZHEIMER NETWORK, THE STUDY OF MUTATION CAUSED AD AND PREVENTION TRIALS

^○Randall Bateman (Washington University is St. Louis School of Medicine, USA)

Dr. Bateman is the Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Dominantly Inherited Alzheimer Network (DIAN), and Director of the DIAN Trials Unit (DIAN-TU). Dr. Bateman’s research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer’s disease. His lab recently reported on an accurate blood test for Alzheimer’s disease plaques. Dr. Bateman’s research in DIAN has provided evidence for a cascade of events beginning decades before symptom onset that leads to AD dementia, supporting development of Alzheimer’s disease prevention trials.

Dr. Bateman directs the DIAN-TU, which launched the first prevention trial in families with early onset Alzheimer’s disease in 2012. The DIAN-TU trial is an advanced world-wide adaptive trial platform that tests the most advanced therapeutics targeting early onset dominantly inherited Alzheimer’s disease. The DIAN-TU has now launched it’s third drug arm, an oral medication that blocks amyloid-beta formation with the goal to slow, stop or reverse Alzheimer’s disease.

Dr. Bateman has received a number of awards including the Beeson Award for Aging Research, Alzheimer’s Association (Zenith Award), Scientific American, Chancellor’s Award for Innovation and Entrepreneurship, the Glenn Award for Aging Research, and the MetLife Foundation Award for Medical Research.